Invitrogen to Sell BioReliance for $210M; Posts Weak Revenue Gain and $100M Loss in Q4 | GenomeWeb
NEW YORK (GenomeWeb News) — Invitrogen plans to sell its BioReliance unit to Avista Capital Partners for $210 million as part f Invitrogen’s ongoing plan to better organize its acquired components, the companies said late yesterday.  
Separately yesterday, Invitrogen reported weak fourth-quarter revenue growth as R&D spending decreased 7.6 percent and net income dropped 300 percent on a variety of one-time charges.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.